China NMPA Drug Inspection - Client: Yunnan Longfa Pharmaceutical Co., Ltd.; Contractor: Yunnan Longrun Pharmaceutical Co., Ltd. - Pudilan Anti-inflammatory Tablets
China NMPA drug inspection for Client: Yunnan Longfa Pharmaceutical Co., Ltd.; Contractor: Yunnan Longrun Pharmaceutical Co., Ltd. published June 01, 2020. Drug: Pudilan Anti-inflammatory Tablets. On June 1, 2020, the Guangxi Medical Products Administration, under the National Medical Products Administration (NMPA),
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Client: Yunnan Longfa Pharmaceutical Co., Ltd.; Contractor: Yunnan Longrun Pharmaceutical Co., Ltd. published June 01, 2020. Drug: Pudilan Anti-inflammatory Tablets. On June 1, 2020, the Guangxi Medical Products Administration, under the National Medical Products Administration (NMPA),
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox